Previous close | 273.65 |
Open | 274.41 |
Bid | 280.26 x 200 |
Ask | 281.04 x 100 |
Day's range | 272.53 - 280.59 |
52-week range | 176.34 - 413.20 |
Volume | |
Avg. volume | 624,364 |
Market cap | 21.108B |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | 46.27 |
EPS (TTM) | 6.06 |
Earnings date | 24 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 338.96 |
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.